TMCnet News
Medigene to present first pre-clinical data for MDG1015 with poster presentation at AACR 2023 Annual MeetingMartinsried/Munich, March 16, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present a poster at the American Association for Cancer Research Virtual Annual Meeting (AACR) 2023 being held on April 14-19, 2023. The work to be presented shows that T cells carrying a NY-ESO-1-specific T cell receptor (TCR) combined with a chimeric PD1-41BB switch receptor, have significantly increased TCR-T cell proliferation, functionality and anti-tumor activity, compared to T cells expressing the TCR alone. A potential mechanism associated with this enhanced functionality is the greater release of multiple different effector cytokines. The abstract for this research has been published online at https://www.abstractsonline.com/pp8/#!/10828/presentation/3341 and posters will be available online on April 18, 2023. Poster details 4057/9: T cells co-expressing a highly potent NY-ESO-1-specific TCR and a chimeric PD1-41BB co-stimulatory switch receptor show a favorable polyfunctional profile for the treatment of solid tumors Andrea Coluccio, Stefanie Tippmer, Petra Prinz, Maja Buerdek, Kathrin Mutze, Barbara Loesch, Kathrin Davari, Giulia Longinotti, Doores J. Schendel. Session details: Adoptive Cell and Natural Killer Cell Therapy --- end of press release --- About Medigene For more information, please visit www.medigene.com About Medigene’s TCR-T Therapy Platform About Medigene’s MDG1015 Program This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only. Contacts Medigene AG Pamela Keck LifeSci Advisors Sandya von der Weid In case you no longer wish to receive any information about Medigene, please inform us by e-mail ([email protected]). We will then delete your address from our distribution list.
![]() |